Interstitial Pneumonia Related to Undifferentiated Connective Tissue Disease Pathologic Pattern and Prognosis

Size: px
Start display at page:

Download "Interstitial Pneumonia Related to Undifferentiated Connective Tissue Disease Pathologic Pattern and Prognosis"

Transcription

1 [ Original Research Diffuse Lung Disease ] Interstitial Pneumonia Related to Undifferentiated Connective Tissue Disease Pathologic Pattern and Prognosis Ho-Cheol Kim, MD ; Wonjun Ji, MD ; Mi Young Kim, MD, PhD ; Thomas V. Colby, MD, PhD ; Se Jin Jang, MD, PhD ; Chang-Keun Lee, MD, PhD ; Seung Bong Han, PhD ; and Dong Soon Kim, MD, PhD BACKGROUND: Undifferentiated connective tissue disease (UCTD) involves conditions characterized by both having symptoms of connective tissue disease (CTD) and autoantibodies but not fulfilling the criteria of a specific CTD. The frequency or prognosis of the usual interstitial pneumonia (UIP) pattern in UCTD is unknown, which may be confused with idiopathic pulmonary fibrosis (IPF). This study aimed to investigate the frequency of the UIP pattern in interstitial pneumonia related to UCTD and compare its prognosis with that of IPF and UCTD-nonspecific interstitial pneumonia (UCTD-NSIP). METHODS: The medical records of 788 patients presumptively diagnosed with idiopathic interstitial pneumonia at Asan Medical Center from January 2005 to December 2012 were retrospectively reviewed. UCTD was diagnosed according to the criteria by Corte and colleagues, and the prognoses were compared between UCTD-UIP and UCTD-NSIP and between UCTD-UIP and IPF. RESULTS: Among 105 patients with UCTD (13.3% of total subjects), 44 had a UIP pattern (by surgical lung biopsy: 24; by high-resolution CT scan: 20), 29 had a nonspecific interstitial pneumonia pattern (by surgical lung biopsy), and nine had an organizing pneumonia pattern (by biopsy). The overall survival of the UCTD-UIP group was shorter than that of the UCTD- NSIP group ( P 5.021) but significantly better than that of the IPF group ( P 5.042). CONCLUSIONS: A UIP pattern, which seems to be frequent in UCTD, showed a poorer prognosis than that of UCTD-NSIP. However, the prognosis of UCTD-UIP was significantly better than that of IPF, highlighting the importance of searching for underlying UCTD in suspected IPF cases. CHEST 2015; 147 ( 1 ): Manuscript received February 2, 2014; revision accepted August 10, 2014; originally published Online First September 11, ABBREVIATIONS: ANA 5 antinuclear antibody; CTD 5 connective tissue disease; Dlco 5 diffusing capacity of the lung for carbon monoxide; ENA 5 extractable nuclear antigen; HRCT 5 high-resolution CT; IIP 5 idiopathic interstitial pneumonia; ILD 5 interstitial lung disease; IPF 5 idiopathic pulmonary fibrosis; NSIP 5 nonspecific interstitial pneumonia; OP 5 organizing pneumonia; RF 5 rheumatoid factor; UCTD 5 undifferentiated connective tissue disease; UCTD-IP 5 interstitial pneumonia related to undifferentiated connective tissue disease; UIP 5 usual interstitial pneumonia AFFILIATIONS: From the Department of Pulmonary and Critical Care Medicine (Drs H.-C. Kim, Ji, and D. S. Kim) and Department of Radiology (Dr M. Y. Kim), Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea; Department of Laboratory Medicine and Pathology (Dr Colby), Mayo Clinic, Scottsdale, AZ; and the Department of Pathology (Dr Jang), Division of Rheumatology, Department of Internal Medicine (Dr Lee), and Department of Clinical Epidemiology and Biostatistics (Dr Han), Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea. Drs H.-C. Kim and Ji contributed equally as the co-first authors. FUNDING/SUPPORT: The authors have reported to CHEST that no funding was received for this study. CORRESPONDENCE TO: Dong Soon Kim, MD, PhD, Department of Pulmonary and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea ; dskim615@gmail.com 2015 AMERICAN COLLEGE OF CHEST PHYSICIANS. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: /chest journal.publications.chestnet.org 165

2 Undifferentiated connective tissue disease (UCTD) is a clinical entity as described in the rheumatology community characterized by features that are suggestive of connective tissue disease (CTD) but not fulfilling the classification criteria for a specific CTD. 1,2 Kinder et al 3 reported that most patients with a nonspecific interstitial pneumonia (NSIP) pattern on surgical lung biopsy met their case definition of UCTD. Later, several authors also reported the common occurrence of UCTD in surgical lung biopsy-proven NSIP, 4-6 suggesting that most idiopathic NSIP may actually be the lung manifestation of UCTD. 3 However, the diagnostic criteria for UCTD differ, and Kinder et al 3 used broad criteria, including nonspecific features like elevated erythrocyte sedimentation rate or gastroesophageal reflux, that might result in an overestimation of UCTD. Furthermore, although the NSIP pattern was first described and seems to be the predominant pattern in UCTD, no study, to our knowledge, has investigated the relative frequency of NSIP or usual interstitial pneumonia (UIP) patterns in UCTD. Vij et al 7 reported that the UIP pattern was the most common pattern in autoimmune-featured interstitial pneumonia, suggesting that the UIP pattern may be more frequent than previously thought. In other aspects, the prognosis of idiopathic pulmonary fibrosis (IPF) is much poorer than that of a UIP pattern related to classic CTD, with the possible exception of rheumatoid arthritis Moreover, autoantibodies like antinuclear antibody (ANA) and rheumatoid factor (RF) are frequently found in patients with IPF, 11 suggesting that UCTD may also be present but undiagnosed in these patients. Consequently, it is clinically important to know the frequency of UCTD in patients with presumptive diagnosis of IPF and the difference in prognosis between UCTD-UIP and IPF. This study aimed to investigate the relative frequency of UIP and NSIP patterns in patients with UCTD-related interstitial pneumonia (UCTD-IP) and their prognostic differences, and to compare the prognoses for UCTD-UIP and IPF. Materials and Methods Study Population A total of 788 patients seen at Asan Medical Center due to presumptive idiopathic interstitial pneumonia (IIP) from January 2005 to December 2012 were included in this study. Patients with classic CTDs or an exposure history in relation to the possible causes of interstitial lung disease (ILD), such as drugs or environmental agents, were excluded. Data were retrospectively collected from medical records. A thorough systematic history, including any rheumatologic symptoms and signs, with serologic testing for CTD was obtained from all subjects at the time of initial diagnosis and intermittently during follow-up. Many of the patients analyzed here had been included in our previous studies. 12,13 Because this study was a retrospective review of medical records, written informed consent was waived. The study protocol was approved by the institutional review board of Asan Medical Center (approval number ). Autoantibody Test All patients underwent serologic tests for autoantibodies at the time of diagnosis. ANA was tested in the serum with a commercially available prestandardized kit (ANA/HEp-2 Test System; ZEUS Scientific, Inc). Any sample that had a positive result above 1:160 titer was considered positive. Extractable nuclear antigens (ENAs) were tested with an ENA Combi ELISA kit (BL Diagnostika). A signal-to-cut-off ratio. 1.0 was considered positive. ENAs testing included anti-ro (SS-A), anti-la (SS-B), anti-scl-70, anti-ribonucleoprotein, and Jo-1 antibodies. RF was measured with a commercially available kit (RapiTexRF; Dade Behring Inc/ Siemens Medical Solutions) that uses slide latex agglutination for qualitative measurements. Any sample that had a positive result at above a 1:160 International Unit was considered positive. Histopathology Surgical lung biopsy was performed in 363 patients and transbronchial lung biopsy in 11 patients. The biopsy specimen slides of patients with UCTD were rereviewed independently by two pathologists (T. V. C., S. J. J.) who were blind to the clinical findings. Final consensus histopathologic diagnosis was made according to the American Thoracic Society/European Respiratory Society international consensus classification of IIPs. 14 High-Resolution CT Scan High-resolution CT (HRCT) scan was performed at baseline in all patients and followed up annually or at a time of acute change in the patient s condition. The HRCT scan images were reviewed in a blind manner by the radiologist (M. Y. K.) with. 10 years experience in ILD. The HRCT scan pattern was categorized as the typical UIP pattern or as a non-uip pattern. 14 Because the typical UIP pattern in HRCT scans was recently shown to be highly specific for the pathologic UIP pattern in patients with rheumatoid arthritis similar to IPF, we used this HRCT scan pattern for the diagnosis of UCTD-UIP. 15 Diagnostic Criteria for UCTD and Follow-up Course The narrower diagnostic criteria for UCTD recommended by Corte et al 4 were used, that is, the presence of one or more of the specific autoantibodies combined with more than one symptom or sign of CTD (including Raynaud s phenomenon, sicca symptoms, arthralgia, morning stiffness, or proximal muscle weakness). 4,16 All final diagnoses were made via the multidisciplinary approach that included experienced pathologists, clinicians, and radiologists. The diagnosis of IPF was reconfirmed according to the new American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society guidelines. 17 The clinical follow-up courses and survival statuses of the patients until July 2013 were obtained from medical records, National Health Insurance of Korea records, and/or telephone interviews. Treatment responses were categorized as improvement, stable, or deterioration according to the change in the pulmonary function test. 17,18 Improvement/deterioration was defined as a change of 10% in the FVC and/or 15% in the diffusing capacity of the lung for carbon monoxide (D lco ). 18 Statistical Analysis The comparisons of baseline characteristics and treatments were made using a Student t test for continuous variables and a x 2 or Fisher exact test for categorical data. All P values were two-tailed, with statistical significance set at P,.05. Kaplan-Meier survival analysis was used to evaluate the differences in survival rates and risk factors for mortality were analyzed with Cox proportional hazards models. Statistical analyses were performed with SPSS, version 18.0 for Windows (IBM). 166 Original Research [ 147 # 1 CHEST JANUARY 2015 ]

3 Results Patient Characteristics and the Frequency of Pathologic Patterns in UCTD Among the 788 patients with presumptive IIP, 105 (13.3%) met the UCTD criteria. Patients with UCTD were younger (59.0 years vs 65.1 years) and more likely to be female (62.4% vs 21.8%) than patients with non-uctd-iip. The most common rheumatologic symptom was arthralgia (59.0%), and the most common laboratory finding was positive ANA (51.4%) ( Table 1 ). The k value for histologic classification between two pathologists was Among the 105 patients with UCTD, 44 had the UIP pattern (24 by surgical lung biopsy and 20 by the typical UIP pattern on HRCT scan), and 29 patients had the NSIP pattern (all diagnosed by surgical lung biopsy). An organizing pneumonia (OP) pattern was found in nine patients (by transbronchial lung biopsy in four patients, by surgical lung biopsy in five patients), and the pathologic type of the remaining 23 patients was uncertain because no surgical lung biopsy was performed. The UCTD-NSIP group (52.5 years of age) was younger than the UCTD-UIP group (62.8 years of age). BAL and baseline pulmonary function test results were not significantly different between the two groups ( Table 2 ). Among 683 patients with proven IIP, 499 (73.1%) were diagnosed as IPF, 81 (11.9%) as idiopathic NSIP (biopsy-proven), and 59 (8.6%) a cryptogenic OP (biopsy-proven; seven cases by transbroncheal lung biopsy). The pattern of the remaining patients was uncertain because no surgical lung biopsy was performed. Among the patients with the UIP pattern, the prevalence of UCTD was 8.1%. Among the NSIP pattern, UCTD was found in 26.3%. Treatment and Response of UCTD-IP Treatment with steroids alone or with immunosuppressant was given to 77 patients (73.3%) according to the attending physician s judgment. The remaining patients were not treated either because the disease was mild, or due to patient refusal. There were no significant differences in the treatment regimen or response to therapy between the UCTD-UIP and UCTD-NSIP groups (Table 3 ). Comparison of the Prognosis Between UCTD-UIP and UCTD-NSIP The survival period of patients with UCTD-NSIP was significantly longer than those with UCTD-UIP TABLE 1 ] Baseline Characteristics of 105 Patients With UCTD Characteristics UCTD-IP Age, mean SD, y Sex, male 29 (27.6) Smoking (ever smoker) 30 (28.6) Symptoms Arthralgia 62 (59.0) Sicca symptom 56 (53.3) Raynaud phenomenon 32 (30.5) Morning stiffness 11 (10.5) Muscle weakness 1 (1.0) Autoantibody ANA (titer 160) 54 (51.4) SS-A (Ant-Ro) 40 (38.1) Anti-Jo-1 15 (14.3) Scl (11.4) RF (titer 160) 6 (5.7) Anti-RNP 5 (4.8) SS-B (Ant-La) 2 (1.9) Positive two antibodies 23 (21.9) Positive three antibodies 4 (3.8) HRCT scan pattern Typical UIP pattern 32 (30.5) Non-UIP pattern 73 (69.5) Surgical lung biopsy (No. 558) UIP 24 (41.4) NSIP 29 (50.0) OP 5 (8.6) Final pattern UIP 44 NSIP 29 OP 9 Uncertain 23 Values are reported as mean SD or as frequency (%). ANA 5 antinuclear antibody; HRCT 5 high-resolution CT; NSIP 5 nonspecific interstitial pneumonia; OP 5 organizing pneumonia; RF 5 rheumatoid factor; RNP 5 ribonucleoprotein; SS 5 Sjogren syndrome; UCTD 5 undifferentiated connective tissue disease; UCTD-IP 5 interstitial pneumonia related to undifferentiated connective tissue disease; UIP 5 usual interstitial pneumonia. ( P 5.021) ( Fig 1 ). The univariate Cox proportional hazards model showed that the UCTD-NSIP pattern was a significant independent prognostic factor (hazard ratio, 0.256; 95% CI, ; P 5.033). However, in the multivariate Cox proportional hazards model, a UCTD-NSIP pattern was not a significant independent prognostic factor ( Table 4 ). journal.publications.chestnet.org 167

4 TABLE 2 ] Comparison of the Baseline Features Between the UCTD-UIP and UCTD-NSIP Groups Features UIP NSIP P Value Patient number 44 (41.9) 29 (27.6) Age, y ,.005 Sex, male 15 (34.1) 6 (20.7).216 Smoking (ever smoker) 16 (36.4) 6 (20.7).153 BAL (UIP: No. 5 34; NSIP: No. 5 18) WBC count, / m L Neutrophil, % Lymphocyte, % Baseline PFT (UIP: No. 5 44; NSIP: No. 5 29) FVC, % FEV 1, % D LCO, % TLC, % MWT, distance Values are reported as mean SD or as frequency (%). 6MWT 5 6-min walk test; D LCO 5 diffusing capacity of the lung for carbon monoxide; PFT 5 pulmonary function test; TLC 5 total lung capacity. See Table 1 legend for expansion of other abbreviations. Because the pathologic pattern was not confirmed in 23 patients, the clinical features and survival curves of these patients were compared separately. As shown in Table 2, there was no difference in the clinical features between UCTD-UIP and UCTD-NSIP except age and the age of these 23 patients with uncertain pathologic pattern was years, similar to UCTD-UIP TABLE 3 ] Clinical Course of the Patients With UCTD-UIP and UCTD-NSIP Characteristics UCTD-UIP UCTD-NSIP P Value Patient number Treatment regimen.695 Steroid only 17 (38.6) 13 (44.8) Steroid 1 immunosuppressant 14 (31.8) 10 (34.5) None 13 (29.5) 6 (20.7) Treatment response (UCTD-UIP: No. 5 31; UCTD-NSIP: No. 5 23) Improvement 5 (16.1) 3 (13.0) Stable 19 (61.3) 17 (73.9) Deterioration 7 (22.6) 3 (13.0).619 Median follow-up, mo Survival (%) y y Values are reported as frequency (%). See Table 1 legend for expansion of abbreviations. group ( years) ( e-table 1 ). And the survival of these patients was also similar to that of the UCTD-UIP group ( e-fig 1 ). Comparison of the Survival Between IPF and UCTD-UIP The baseline characteristics of the IPF and UCTD-UIP groups were summarized in Table 5. Kaplan-Meier survival analysis showed significantly better prognosis of the UCTD-UIP group (n 5 44) than the IPF group ( P 5.042) (Fig 2 ). The univariate Cox proportional Figure 1 Comparison of the survival curves of the patients with UCTD-UIP and UCTD-NSIP. NSIP 5 nonspecific interstitial pneumonia; UCTD 5 undifferentiated connective tissue disease; UIP 5 usual interstitial pneumonia. 168 Original Research [ 147 # 1 CHEST JANUARY 2015 ]

5 TABLE 4 ] Predicting Factors for Mortality in Patients With UCTD-IP Assessed by Cox Proportional Hazards Model Parameters Hazard Ratio 95% CI P Value Univariate analysis NSIP diagnosis Sex, female Age Ever smokers BAL WBC count, / m L BAL neutrophil, % BAL lymphocyte, % FVC, % FEV 1, % D LCO, % TLC, % MWT, distance Treatment with steroid or immunosuppressant Multivariate analysis a NSIP diagnosis Age Sex, female FVC See Table 1 and 2 legends for expansion of abbreviations. a For the multivariate analysis, a total of 73 patients (UCTD-UIP 44 patients, UCTD-NSIP 29 patients) were evaluated. The covariates for the full model were diagnosis, age, sex, and FVC. Among the covariates significant in the univariate analysis, TLC was not included in the full model because of high correlation with FVC. hazards model revealed that UCTD-UIP was a significant independent prognostic factor for a reduced mortality of 43% compared with the IPF group (hazard ratio, 0.576; 95% CI, ; P 5.045). On multivariate analysis, UCTD-UIP pattern was a significant independent prognostic factor (hazard ratio, 0.565; 95% CI, ; P 5.030) ( Table 6 ). Interestingly, our data suggested that the treatment with steroid or immunosuppressant had a negative effect (worse prognosis) in the patients with IPF, however, it should be interpreted cautiously because the sicker, progressing patients are more likely to receive such therapy. Comparison of the Survival Between Idiopathic NSIP and UCTD-NSIP We compared UCTD-NSIP with idiopathic NSIP ( e-table 2 ). Kaplan-Meier survival analysis showed no significant differences in survival between the two groups (e-fig 2 ). Follow-up and Development of Definite CTD The median follow-up duration of patients with UCTD was 32.3 months (interquartile range, months). During follow-up, three patients (2.9%) developed definite CTD. Clinical characteristics of these three patients are presented in e-table 3. Discussion Our current study showed that the UIP pattern was as common as the NSIP pattern in patients with UCTD, and the prognosis of UCTD-UIP was better than that of IPF, although there was no difference in survival between UCTD-NSIP and idiopathic NSIP. Our data support the importance of differentiation between IPF and UCTD-UIP, although UCTD may not be easily recognized and may be misdiagnosed as IPF. Although the presence of underlying CTD is crucial both for prognosis and treatment in the patients with interstitial pneumonia, there is a subset of patients with symptoms, signs, and serologic tests suggestive of an underlying autoimmune disease but they do not fulfill all of the diagnostic criteria for a specific CTD. These patients have been designated as having UCTD. However, a conceptual discrepancy exists for UCTD between rheumatologists and pulmonologists. 19,20 Furthermore, the diagnostic criteria for UCTD are highly variable. Therefore, several different terminologies have been proposed to categorize these patients, such as lungdominant CTD by Fischer et al 19 and autoimmunefeatured ILD by Vij et al. 7 However, the criteria of autoimmune-featured ILD included several nonspecific symptoms like weight loss, gastroesophageal reflux, or dysphagia and those for lung-dominant CTD included histopathologic features of surgical lung biopsy specimen. Therefore, we decided to investigate UCTD using the criteria accepted by both rheumatologists and pulmonologists. In contrast to other UCTD studies, 2,5 we have reviewed all of the patients with presumptive IIP, including those with undetermined histopathologic patterns due to the lack of surgical lung biopsy. Although this study was a retrospective analysis, we prospectively collected all data on clinical features and the presence of blood autoantibodies from the beginning. We found that 13.3% of the patients with presumptive IIP had UCTD, which is lower than the 21% reported by Corte et al 4 who only investigated the patients on whom surgical lung biopsy was performed, resulting in higher prevalence of the NSIP pattern (45%) compared with other series (in our cohort, 11.9%). Because UCTD is more common in the NSIP pattern, consequently they might have found higher frequency of UCTD among the journal.publications.chestnet.org 169

6 TABLE 5 ] Comparison Between IPF and UCTD-UIP Features IPF UCTD-UIP P Value Patient number Age, y Sex, male 390 (78.2) 15 (34.1),.005 Smoking (ever smoker) 355 (71.1) 16 (36.4),.005 Surgical lung biopsy 204 (40.9) 24 (54.5).080 BAL (IPF: No ; UCTD-UIP: No. 5 34) WBC count, / m L Neutrophil, % Lymphocyte, % Baseline PFT, frequency (%) (IPF: No ; UCTD-UIP: No. 5 44) FVC FEV D LCO TLC MWT, distance Median follow-up, mo Survival (%) y y Values are reported as mean SD or as frequency (%). IPF 5 idiopathic pulmonary fibrosis. See Table 1 and 2 legends for expansion of other abbreviations. total subjects. Vij et al 7 reported that the prevalence of autoimmune-featured ILD was 52% of presumable IIP; however, their criteria included several nonspecific features as mentioned previously. Figure 2 Kaplan-Meier survival curves of the patients with UCTD-UIP and IPF. IPF 5 idiopathic pulmonary fibrosis. See Figure 1 legend for expansion of other abbreviations. Although the frequency of UCTD was three times higher in the NSIP than in the UIP pattern, our current study showed that in patients with ILD and UCTD, the UIP pattern was as frequent as or more frequent than the NSIP pattern, which was consistent with the findings of Vij et al 7 (25 UIP pattern vs two NSIP pattern among 63 patients with autoimmune-featured ILD). We also confirmed that among the patients with UCTD, the overall prognosis was better for patients with the NSIP pattern than those with the UIP pattern, although not significant on multivariate analysis. Furthermore, Kaplan-Meier survival analysis showed a significant difference between UCTD-UIP and IPF; the presence of UCTD in the patients with the UIP pattern was a significant independent prognostic factor on multivariate analysis. Previously, Corte et al 4 reported that UCTD was not associated with a survival benefit, which may be due to smaller numbers (total 101 patients) of the subject compared with ours. Recently, Strand et al 21 also reported that there was no significant difference in survival between UCTD-UIP and IPF. However, the number of their subjects was small (UCTD-UIP: 19 patients). Furthermore, there was no mention about the diagnostic criteria of UCTD, which may affect the 170 Original Research [ 147 # 1 CHEST JANUARY 2015 ]

7 TABLE 6 ] Predicting Factors for Mortality in Patients With IPF and UCTD-UIP Assessed by Cox Proportional Hazards Model Parameters Hazard Ratio 95% CI P Value Univariate analysis UCTD-UIP diagnosis Sex, female Age Ever smokers BAL WBC count, / m L BAL neutrophil, % BAL lymphocyte, % FVC, % ,.001 FEV 1, % ,.001 D LCO, % ,.001 TLC, % ,.001 6MWT, distance ,.001 Treatment with steroid or immunosuppressant Multivariate analysis a UCTD-UIP diagnosis Age Sex, female FVC ,.001 Treatment with steroid or immunosuppressant See Table 1, 2, and 5 legends for expansion of abbreviations. a For the multivariate analysis, the covariates for the full model were diagnosis, age, sex, and FVC. Among the covariates significant in the univariate analysis, BAL neutrophil was not included in the multivariate analysis because of the high proportion of the missing data and FEV 1, and TLC due to high correlation with FVC. results. Our previous study showed that the mere presence of autoantibody had no influence on survival in the patients with IPF. 12 This study demonstrated, for the first time, to our knowledge, that the prognosis of UCTD-UIP was better than that of IPF, reenforcing the importance of diagnosing associated UCTD in patients with suspected IPF. Considering the failure of prior studies demonstrating the difference between IPF and UCTD (using broad criteria)-uip, 4,7,21 it is important to use strict diagnostic criteria for UCTD, both relevant symptoms and serology (higher titer). Because there was no significant difference in prognosis between UCTD-NSIP and idiopathic NSIP, we focused on comparing UCTD-UIP and IPF. Three of the patients developed definite CTD during follow-up as reported before showing the necessity of close monitoring regardless of the histologic pattern. There are several limitations to this study. First, our study was retrospective in design. However, the subjects were from prospectively recruited cohorts with little missing data. Another limitation was that the pathologic pattern of 30.5% of the patients with UCTD-IP was not confirmed. However, the only significant difference between UCTD-UIP and UCTD-NSIP was age ( Table 2 ) and the age of UCTD-undetermined pathology group was similar to the UCTD-UIP group so as to the survival curves. If all of these patients had had an NSIP pattern, the results would not have been different except that the prevalence of UCTD-NSIP would have increased to 49.5%. Because the old age (. 65 years, particularly among males) is strongly associated with UIP-pattern pathology in patient IIP but without the typical UIP pattern of HRCT scans (without honeycombing), 25 we reanalyzed the data as old age male patients with UCTD without biopsy (n 5 2) having UCTD-UIP. The results were the same (better survival of UCTD-UIP, hazard ratio, 0.529; 95% CI, ; P 5.026). Third, although we adopted narrow criteria of UCTD including a high titer of ANA (. 1:160), it may be somewhat liberal and ANA titer could change, if repeated. In the subjects, ANA titer was 1:1280 in six patients, 1:640 in nine, 1:320 in 23, and 1:160 in 16 patients. Repeated tests were performed in 28 patients; the results were journal.publications.chestnet.org 171

8 the same (. 1:160) in 25 patients. The titer was reduced in three patients, however, they were measured during the therapy with steroid and immunosuppressant. Furthermore, there is an innate difficulty in distinguishing arthralgias from osteoarthritis. However, most of the subjects, especially with UCTD were seen by a rheumatologist, and we think the possibility of misclassification was low. Finally, although this is the largest series of UCTD-IP cases reported to date, the numbers are still relatively small and from a single center. Thus, a multinational multiinstitutional prospective study with a larger number of patients is needed in the future. In conclusion, our current study findings confirm that a UIP pattern is frequently seen in patients with UCTD. Moreover, a significant proportion of patients with IPF have underlying UCTD and it is important to differentiate these patients from those with IPF because of the better prognosis of patients with UCTD-UIP. Acknowledgments Author contributions: D. S. K. has been identified as the guarantor of the paper, taking responsibility for the integrity of the work as a whole, from inception to published article. D. S. K. contributed to study conception and design; H.-C. K., W. J., M. Y. K., C.-K. L., and T. V. C. contributed to data acquisition; H.-C. K., W. J., and D. S. K. contributed to data analysis and interpretation; S. B. H. performed statistical analysis; H.-C. K., W. J., and D. S. K. contributed to the writing of the manuscript; and D. S. K, H.-C. K., W. J., M. Y. K., C.-K. L., T. V. C., and S. B. H. contributed to manuscript review and acceptance. Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Additional information: The e-figures and e-tables can be found in the Supplemental Materials section of the online article. References 1. Mosca M, Tani C, Neri C, Baldini C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev ;6(1): Mosca M, Tani C, Carli L, Bombardieri S. Undifferentiated CTD: a wide spectrum of autoimmune diseases. Best Pract Res Clin Rheumatol ;26(1): Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med ;176(7): Corte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J ; 39 ( 3 ): Suda T, Kono M, Nakamura Y, et al. Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD). Respir Med ;104(10): Lunardi F, Balestro E, Nordio B, et al. Undifferentiated connective tissue disease presenting with prevalent interstitial lung disease: case report and review of literature. Diagn Pathol ;6: Vij R, Noth I, Strek ME. Autoimmunefeatured interstitial lung disease: a distinct entity. Chest ; 140 ( 5 ): Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular diseaserelated subtypes. Am J Respir Crit Care Med ;175(7): Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest ;136(5): Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J ;35(6): Lee JS, Kim EJ, Lynch KL, et al. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med ;107(2): Kang BH, Park JK, Roh JH, et al. Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia. J Korean Med Sci ;28(5): Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest ;143(5): Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J ;19(5): Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology ;270(2): Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol ;17(5): Raghu G, Collard HR, Egan JJ, et al ; ATS/ ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med ;183(6): Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) ;65(5): Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue diseaseassociated interstitial lung disease: a call for clarification. Chest ; 138 ( 2 ): Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest ; 143 (3): Strand MJ, Sprunger D, Cosgrove GP, et al. Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest ; 146 ( 3 ): Bodolay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol ;21(3): Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G. Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol ;17(3): Guerrero LF, Rueda JC, Arciniegas R, Rueda JM. Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year. Rheumatol Int ;33(4): Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med ; 181 ( 8 ): Original Research [ 147 # 1 CHEST JANUARY 2015 ]

CTD-related Lung Disease

CTD-related Lung Disease 13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of

More information

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment

Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,

More information

Clinical characteristics and survival in idiopathic pulmonary fibrosis and connective tissue disease-associated usual interstitial pneumonia

Clinical characteristics and survival in idiopathic pulmonary fibrosis and connective tissue disease-associated usual interstitial pneumonia Original Article Clinical characteristics and survival in idiopathic pulmonary fibrosis and connective tissue disease-associated usual interstitial pneumonia Esam H. Alhamad Department of Medicine, College

More information

Diffuse Interstitial Lung Diseases: Is There Really Anything New?

Diffuse Interstitial Lung Diseases: Is There Really Anything New? : Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There

More information

[ Original Research Diffuse Lung Disease ]

[ Original Research Diffuse Lung Disease ] [ Original Research Diffuse Lung Disease ] Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis Christopher

More information

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to

More information

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary

More information

Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia

Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia Original article: Clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2013; 30; 103-112 Mattioli 1885 Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia

More information

UC Davis UC Davis Previously Published Works

UC Davis UC Davis Previously Published Works UC Davis UC Davis Previously Published Works Title Characterisation of patients with interstitial pneumonia with autoimmune features Permalink https://escholarship.org/uc/item/0n40x0jb Journal European

More information

Connective Tissue Disease-Associated Interstitial Lung Disease

Connective Tissue Disease-Associated Interstitial Lung Disease CHEST Commentary Connective Tissue Disease-Associated Interstitial Lung Disease A Call for Clarification Aryeh Fischer, MD ; Sterling G. West, MD ; Jeffrey J. Swigris, DO ; Kevin K. Brown, MD ; and Roland

More information

Significance of connective tissue disease features in idiopathic interstitial pneumonia

Significance of connective tissue disease features in idiopathic interstitial pneumonia Eur Respir J 2012; 39: 661 668 DOI: 10.1183/09031936.00174910 CopyrightßERS 2012 Significance of connective tissue disease features in idiopathic interstitial pneumonia T.J. Corte*,#,", S.J. Copley*,+,

More information

Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease

Disclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor

More information

Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Disease: Changes in Lung Function

Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Disease: Changes in Lung Function Lung (2010) 188:143 149 DOI 10.1007/s00408-009-9226-7 Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Disease: Changes in Lung Function Brent W. Kinder Cyrus Shariat Harold R. Collard

More information

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD)

ERS 2016 Congress Highlights Interstitial Lung Disease (ILD) ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the

More information

The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page

The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page 1135-1140 Role of High Resolution Computed Tomography in Diagnosis of Interstitial Lung Diseases in Patients with Collagen Diseases

More information

Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy

Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe

More information

DIAGNOSTIC NOTE TEMPLATE

DIAGNOSTIC NOTE TEMPLATE DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the

More information

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease Eur Respir J 2010; 35: 1322 1328 DOI: 10.1183/09031936.00092309 CopyrightßERS 2010 Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease E.J. Kim*, B.M. Elicker #, F.

More information

Imaging: how to recognise idiopathic pulmonary fibrosis

Imaging: how to recognise idiopathic pulmonary fibrosis REVIEW IDIOPATHIC PULMONARY FIBROSIS Imaging: how to recognise idiopathic pulmonary fibrosis Anand Devaraj Affiliations: Dept of Radiology, St George s Hospital, London, UK. Correspondence: Anand Devaraj,

More information

Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD)

Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD) Respiratory Medicine (2010) 104, 1527e1534 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling

More information

A Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco

A Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification

More information

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology

5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +

More information

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology

11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment

More information

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation

More information

Diagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016

Diagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016 Diagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016 A/Prof Tamera Corte TSANZ Annual Conference: Perth 2016 Royal Prince Alfred Hospital, Sydney, Australia Sydney Medical School, University

More information

A Review of Interstitial Lung Diseases

A Review of Interstitial Lung Diseases Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification

More information

Case 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar

Case 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar Case 4 History 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar basilar infiltrates suggestive of pulmonary fibrosis Open

More information

IPF: Epidemiologia e stato dell arte

IPF: Epidemiologia e stato dell arte IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic

More information

Diffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious

Diffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious Focused Issue of This Month Diagnostic Approaches to Diffuse Interstitial Lung Diseases Dong Soon Kim, MD Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine E -

More information

Current diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM

Current diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University

More information

Differential diagnosis

Differential diagnosis Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential

More information

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Annual Rheumatology & Therapeutics Review for Organizations & Societies Annual Rheumatology & Therapeutics Review for Organizations & Societies A Rheumatologist s Approach to Interstitial Lung Disease Outline ILD classification and patterns in CTD The clinical landscape and

More information

UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!

UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France CASE OVERVIEW This case highlights how a usual

More information

Outline Definition of Terms: Lexicon. Traction Bronchiectasis

Outline Definition of Terms: Lexicon. Traction Bronchiectasis HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of

More information

Diagnostic challenges in IPF

Diagnostic challenges in IPF Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from

More information

Progress in Idiopathic Pulmonary Fibrosis

Progress in Idiopathic Pulmonary Fibrosis Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim

More information

OFEV MEDIA BACKGROUNDER

OFEV MEDIA BACKGROUNDER OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small

More information

Idiopathic pulmonary fibrosis (IPF) is a

Idiopathic pulmonary fibrosis (IPF) is a Eur Respir J 2011; 38: 176 183 DOI: 10.1183/09031936.00114010 CopyrightßERS 2011 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema S.L. Schmidt*,

More information

Interstitial Pneumonia With Autoimmune Features. Value of Histopathology

Interstitial Pneumonia With Autoimmune Features. Value of Histopathology Interstitial Pneumonia With Autoimmune Features Value of Histopathology Ayodeji Adegunsoye, MD, MS; Justin M. Oldham, MD, MS; Eleanor Valenzi, MD; Cathryn Lee, MD; Leah J. Witt, MD; Lena Chen, BS; Steven

More information

IPF - Inquadramento clinico

IPF - Inquadramento clinico IPF - Inquadramento clinico Sergio Harari Unità Operativa di Pneumologia UTIR Servizio di Fisiopat. Resp. e Emodinamica Polmonare Ospedale S. Giuseppe, Milano Clinical Classification Diffuse parenchimal

More information

Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis

Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis Respiratory Medicine (2013) 107, 249e255 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Prevalence and clinical significance of circulating autoantibodies in idiopathic

More information

International consensus statement on idiopathic pulmonary fibrosis

International consensus statement on idiopathic pulmonary fibrosis Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic

More information

Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas

Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University

More information

The radiological differential diagnosis of the UIP pattern

The radiological differential diagnosis of the UIP pattern 5th International Conference on Idiopathic Pulmonary Fibrosis, Modena, 2015, June 12th The radiological differential diagnosis of the UIP pattern Simon Walsh King s College Hospital Foundation Trust London,

More information

NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP

NONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic

More information

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives

More information

Liebow and Carrington's original classification of IIP

Liebow and Carrington's original classification of IIP Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans

More information

Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis

Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis Original Article Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis Seok Joo 1, Dong Kwan Kim 2, Hee Je Sim

More information

Influence of Smoking in Interstitial Pneumonia Presenting with a Non-Specific Interstitial Pneumonia Pattern

Influence of Smoking in Interstitial Pneumonia Presenting with a Non-Specific Interstitial Pneumonia Pattern ORIGINAL ARTICLE Influence of Smoking in Interstitial Pneumonia Presenting with a Non-Specific Interstitial Pneumonia Pattern Tetsuro Sawata, Masashi Bando, Masayuki Nakayama, Naoko Mato, Hideaki Yamasawa

More information

Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline

Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification

More information

The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome

The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome doi: 10.2169/internalmedicine.8955-17 http://internmed.jp CASE REPORT The Onset of Eosinophilic Pneumonia Preceding Anti-synthetase Syndrome Yoshimasa Hachisu 1, Yasuhiko Koga 1, Noriaki Sunaga 1,2, Chiharu

More information

Disclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None

Disclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona

More information

NOTICE OF SUBSTANTIAL AMENDMENT

NOTICE OF SUBSTANTIAL AMENDMENT NOTICE OF SUBSTANTIAL AMENDMENT For use in the case of all research other than clinical trials of investigational medicinal products (CTIMPs). For substantial amendments to CTIMPs, please use the EU-approved

More information

Nonspecific interstitial pneumonia: survival is influenced by the underlying cause

Nonspecific interstitial pneumonia: survival is influenced by the underlying cause ORIGINAL ARTICLE INTERSTITIAL AND ORPHAN LUNG DISEASE Nonspecific interstitial pneumonia: survival is influenced by the underlying cause Hilario Nunes 1,2, Kirsten Schubel 2, Diane Piver 3, Eline Magois

More information

Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis

Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis Original Article Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis Xia Li 1, Chang Chen 2, Jinfu Xu 1, Jinming Liu 1, Xianghua

More information

Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease

Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease Tohoku J. Exp. Med., 2018, 246, 147-153 Pepsin in Bronchoalveolar Lavage Fluid 147 Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease

More information

COI: no conflicts of interest to declare

COI: no conflicts of interest to declare Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion

More information

Significance of connective tissue diseases features in pulmonary fibrosis

Significance of connective tissue diseases features in pulmonary fibrosis REVIEW RARE DISEASE AND ORPHAN DRUGS Significance of connective tissue diseases features in pulmonary fibrosis Vincent Cottin 1,2 Affiliations: 1 Hospices Civils de Lyon, Hôpital Louis Pradel, Service

More information

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel

A case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical

More information

In idiopathic pulmonary fibrosis (IPF) and

In idiopathic pulmonary fibrosis (IPF) and Eur Respir J 2010; 35: 830 835 DOI: 10.1183/09031936.00155108 CopyrightßERS Journals Ltd 2010 Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

More information

Idiopathic Pulmonary Fibrosis: A Study of 46 Patients from Western India: Clinical Presentations and Survival

Idiopathic Pulmonary Fibrosis: A Study of 46 Patients from Western India: Clinical Presentations and Survival Turk Thorac J 205; 6:4-20 DOI: 0.552/ttd.205.4584 ORIGINAL INVESTIGATION Idiopathic Pulmonary Fibrosis: A Study of 46 Patients from Western India: Clinical Presentations and Survival Subramanian Natarajan,

More information

Myositis and Your Lungs

Myositis and Your Lungs Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes

More information

Unclassifiable interstitial lung disease: A review

Unclassifiable interstitial lung disease: A review bs_bs_banner INVITED REVIEW SERIES EDITORS: TAMERA J. CORTE, ATHOL U. WELLS AND HAROLD R. COLLARD Unclassifiable interstitial lung disease: A review KATE SKOLNIK 1 AND CHRISTOPHER J. RYERSON 2 1 Department

More information

Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias

Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias Respiratory Medicine (2007) 101, 655 660 Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias Yon Ju Ryu a, Man Pyo Chung b,, Joungho Han c, Tae Sung Kim d, Kyung Soo Lee d, Eun-Mi Chun

More information

TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than

TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients

More information

Autoantibodies in the Idiopathic Inflammatory Myopathies

Autoantibodies in the Idiopathic Inflammatory Myopathies Autoantibodies in the Idiopathic Inflammatory Myopathies Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic Rochester, MN The Myositis Association Annual Conference St. Louis, MO Sept. 25,

More information

Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review

Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large retrospective cohort review Alsumrain et al. Respiratory Research (2017) 18:161 DOI 10.1186/s12931-017-0644-4 RESEARCH Utility of autoimmune serology testing in the assessment of uncharacterized interstitial lung disease: a large

More information

An earlier and more confident diagnosis of idiopathic pulmonary fibrosis

An earlier and more confident diagnosis of idiopathic pulmonary fibrosis Eur Respir Rev 2012; 21: 124, 141 146 DOI: 10.1183/09059180.00000812 CopyrightßERS 2012 REVIEW: IPF An earlier and more confident diagnosis of idiopathic pulmonary fibrosis Roland M. du Bois ABSTRACT:

More information

INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)

INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program

More information

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial

More information

Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres

Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres Jo et al. BMC Pulmonary Medicine (2016) 16:22 DOI 10.1186/s12890-016-0179-3 RESEARCH ARTICLE Open Access Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres Helen

More information

IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management

IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management An ATS Pocket Publication This publication was produced in collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. GUIDELINES

More information

Experience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina

Experience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina ORIGINAL 131 RAMR 2017;2:131-135 ISSN 1852-236X Correspondence Gabriela Tabaj gabrielatabaj@gmail.com Received: 11.15.2016 Accepted: 02.03.2017 Experience with the Compassionate Use Program of nintedanib

More information

USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS

USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS USEFULNESS OF HRCT IN DIAGNOSIS AND FOLLOW UP OF PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS Brestas P., Vergadis V., Emmanouil E., Malagari K. 2 nd Dept of Radiology, University of Athens, Greece ABSTRACT

More information

Challenges in the classification of fibrotic ILD

Challenges in the classification of fibrotic ILD Review SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; Suppl. 1: 4-9 Mattioli 1885 Challenges in the classification of fibrotic ILD Elisabeth Bendstrup 1, Toby M. Maher 2, Effrosyni D. Manali

More information

Cardiopulmonary Imaging Original Research

Cardiopulmonary Imaging Original Research Cardiopulmonary Imaging Original Research Chung et al. CT of Usual Interstitial Pneumonia Cardiopulmonary Imaging Original Research Jonathan H. Chung 1 Christian W. Cox 2 Steven M. Montner 2 yodeji degunsoye

More information

Patient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens

Patient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough

More information

Original Article Chronic use of anti-reflux therapy improves survival of patients with pulmonary fibrosis

Original Article Chronic use of anti-reflux therapy improves survival of patients with pulmonary fibrosis Int J Clin Exp Med 2017;10(3):5805-5810 www.ijcem.com /ISSN:1940-5901/IJCEM0043187 Original Article Chronic use of anti-reflux therapy improves survival of patients with pulmonary fibrosis Bo Liu 1,2,

More information

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?

IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.

More information

Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?

Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease? UEF//eRepository DSpace https://erepo.uef.fi Artikkelit Terveystieteiden tiedekunta 2017 Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial

More information

Radiologic pathologic discordance in biopsy-proven usual interstitial pneumonia

Radiologic pathologic discordance in biopsy-proven usual interstitial pneumonia ERJ Express. Published on February 25, 2016 as doi: 10.1183/13993003.01680-2015 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Radiologic pathologic discordance in biopsy-proven usual interstitial pneumonia

More information

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:

Disclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies: Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the

More information

Multidisciplinary Diagnosis in Action: Challenging Case Presentations

Multidisciplinary Diagnosis in Action: Challenging Case Presentations Multidisciplinary Diagnosis in Action: Challenging Case Presentations Interstitial Lung Disease: Advances in Diagnosis and Management UCSF CME November 8, 2014 Case 1 69 yo M 3 year history of intermittent

More information

Clinical Laboratory. [None

Clinical Laboratory. [None Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Double-Stranded DNA (dsdna) Ab IgG ELISA Detected * [None 18-289-900151 Detected] Double-Stranded DNA (dsdna) Ab IgG

More information

Original Article Clinical value of serum KL-6 for lung diseases in patients with polymyositis and dermatomyositis

Original Article Clinical value of serum KL-6 for lung diseases in patients with polymyositis and dermatomyositis Int J Clin Exp Pathol 2017;10(3):3310-3314 www.ijcep.com /ISSN:1936-2625/IJCEP0045527 Original Article Clinical value of serum KL-6 for lung diseases in patients with polymyositis and dermatomyositis Yumeng

More information

Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis

Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis CHEST Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis Jeffrey J. Swigris, DO, MS; Jeff Swick; Frederick S. Wamboldt, MD; David Sprunger, BA, MS;

More information

Diagnosing ILD. What is important in 2016? Chris Grainge

Diagnosing ILD. What is important in 2016? Chris Grainge Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a

More information

Bronchoscopic lung cryobiopsy increases diagnostic confidence. in the multidisciplinary diagnosis of idiopathic pulmonary

Bronchoscopic lung cryobiopsy increases diagnostic confidence. in the multidisciplinary diagnosis of idiopathic pulmonary Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Sara Tomassetti, Athol U Wells, Ulrich Costabel, Alberto Cavazza, Thomas

More information

Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis

Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis Thorax Online First, published on March 22, 2012 as 10.1136/thoraxjnl-2011-201184 Interstitial lung disease < Additional materials are published online only. To view these files please visit the journal

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter

More information

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling

More information

Intracranial lesion as onset symptom in a patient with early undifferentiated connective tissue disease: a case report

Intracranial lesion as onset symptom in a patient with early undifferentiated connective tissue disease: a case report Du et al. BMC Neurology (2017) 17:85 DOI 10.1186/s12883-017-0868-4 CASE REPORT Open Access Intracranial lesion as onset symptom in a patient with early undifferentiated connective tissue disease: a case

More information

Patient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens

Patient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens Patient with IPF and no honeycombing on HRCT Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 76-year-old male patient presented with progressive exertional dyspnoea refractory

More information

Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis

Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Editorial Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Tomoo Kishaba Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Okinawa, Japan

More information

UIP Possibile e Probabile

UIP Possibile e Probabile UIP Possibile e Probabile Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale San Giuseppe - Milano Current definition of IPF IPF is a distinct type

More information

Guidelines for Diagnosis and Treatment of IPF

Guidelines for Diagnosis and Treatment of IPF Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease

More information

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study

Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study 36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E

More information

9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin

9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September 2011 Scleroderma Hard skin 1 No diagnostic test for scleroderma Pathogenesis is unknown prominent features of disease reflect

More information

Pathologic Assessment of Interstitial Lung Disease

Pathologic Assessment of Interstitial Lung Disease Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology

More information